Triple-negative breast cancer (TNBC), accounting for approximately 15–20% of all BC cases, represents a heterogeneous subgroup of BC defined by the absence of the expression of estrogen receptor (ER) and progesterone receptor (PR), as well as of human epidermal growth factor receptor 2 (HER2) overexpression. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.